Last reviewed · How we verify
DF01
DF01 is a small molecule that targets the [unknown] mechanism.
At a glance
| Generic name | DF01 |
|---|---|
| Also known as | tafoxiparin |
| Sponsor | Dilafor AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Further research is needed to understand the exact mechanism of action of DF01.
Approved indications
Common side effects
Key clinical trials
- Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix (PHASE2)
- Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest (PHASE2)
- Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DF01 CI brief — competitive landscape report
- DF01 updates RSS · CI watch RSS
- Dilafor AB portfolio CI